Akorn, Inc. (NASDAQ:AKRX) was the recipient of some unusual options trading activity on Wednesday. Stock investors bought 792 call options on the stock. This is an increase of Infinity compared to the average daily volume of 0 call options.

Several equities analysts have recently commented on the stock. Piper Jaffray Companies reaffirmed a “hold” rating and set a $34.00 price objective on shares of Akorn in a research note on Thursday, August 10th. Royal Bank Of Canada set a $34.00 price objective on shares of Akorn and gave the company a “hold” rating in a research note on Sunday, July 30th. Zacks Investment Research downgraded shares of Akorn from a “hold” rating to a “strong sell” rating in a research note on Friday, August 25th. BidaskClub downgraded shares of Akorn from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $34.00 price objective on shares of Akorn in a research note on Wednesday, July 19th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $28.56.

Akorn (NASDAQ:AKRX) opened at $33.15 on Friday. The company has a current ratio of 4.16, a quick ratio of 4.05 and a debt-to-equity ratio of 0.92. The stock has a market cap of $4.16 billion, a PE ratio of 20.65, a PEG ratio of 1.98 and a beta of 1.33.

Several institutional investors have recently bought and sold shares of AKRX. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Akorn by 22.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock worth $108,000 after buying an additional 599 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Akorn by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock worth $140,000 after buying an additional 626 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Akorn during the 2nd quarter worth approximately $209,000. World Asset Management Inc bought a new position in shares of Akorn during the 2nd quarter worth approximately $210,000. Finally, Suntrust Banks Inc. bought a new position in shares of Akorn during the 2nd quarter worth approximately $234,000. 69.36% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/04/traders-buy-high-volume-of-akorn-call-options-akrx.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.